Viking Therapeutics Accelerates Obesity Drug Trial Enrollment

Viking Therapeutics has achieved a significant advancement in its obesity treatment program, completing patient enrollment for its pivotal Phase 3 clinical trial ahead of schedule. This development positions the biotechnology firm more competitively in the lucrative weight-loss medication sector, where multiple pharmaceutical companies are vying for market share.

The VANQUISH-1 study has successfully enrolled approximately 4,650 adult participants living with overweight or obesity conditions, surpassing initial recruitment targets. This randomized, double-blind, placebo-controlled investigation will evaluate both the safety profile and therapeutic effectiveness of VK2735 across a 78-week treatment period.

The primary objective established for this clinical research is measuring the percentage reduction in body weight compared to placebo following the completion Read more...